Economic Times | Novartis still sees heart failure blockbuster after EU blow Economic Times "Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030, or serelaxin," the Basel-based drugmaker said in a statement. Novartis Denied EU's Nod for Heart-Failure Drug Serelaxin (3) UPDATE 2-Novartis still sees heart failure blockbuster after EU blow Novartis to request re-examination of serelaxin (RLX030) in acute heart ... |
